Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Two-hour assay identifies SA and MRSA in patients with positive blood cultures

BD Diagnostics : 02 January, 2008  (New Product)
BD Diagnostics has received US FDA clearance for the BD GeneOhm StaphSR assay, which is the first test available to rapidly and simultaneously identify two deadly healthcare-associated infections (HAIs) - Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) - from patients with positive blood cultures.
The test will help enable physicians to implement the right treatment at the right time for patients with bloodstream infections, thereby transforming patient care and significantly reducing healthcare costs.

'The BD GeneOhm StaphSR Assay provides a rapid, definitive identification of SA and MRSA from blood cultures. This allows for more appropriate isolation procedures and agent-specific antimicrobial therapy, resulting in reduced patient morbidity and mortality as well as an overall reduction in healthcare costs,' said Thomas Davis, MD, PhD, director of clinical microbiology, Wishard Memorial Hospital, Indianapolis, Indiana, USA.

'The launch of the BD GeneOhm StaphSR Assay in the United States further demonstrates BD's commitment to helping healthcare providers rapidly identify, prevent and control HAIs,' said Vince Forlenza, executive vice president, BD. 'It also illustrates our desire to provide customers with a complete menu of assays and tools to combat these potentially deadly infections.'

The BD GeneOhm StaphSR Assay provides results within two hours, directly from positive blood cultures. It is easy to perform and requires less technologist time than traditional microbiology algorithms, which can take two days to generate results. Studies have shown that providing physicians with critical microbiology information earlier will result in decreased mortality, length of stay and variable costs.

Currently, the BD GeneOhm MRSA Assay rapidly identifies patients who are colonised with MRSA and allows Infection control professionals to break the chain of MRSA transmission. BD has recently submitted subsequent applications to the FDA for the BD GeneOhm StaphSR Assay to add nasal swab and wound claims.

BD is also developing rapid tests for the detection of two other organisms that cause severe HAIs. These tests will identify the vanA and vanB genes associated with vancomycin-resistant enterococci and the toxin gene associated with Clostridium difficile. These rapid assays will further complement the company's portfolio of HAI-related products.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo